. 2012 Jun;21(124):161–167. doi: 10.1183/09059180.00001112

Table 2. All-cause and idiopathic pulmonary fibrosis (IPF)-related mortality in the pooled population.

	Pirfenidone 2403 mg·day^−1#	Placebo^¶	Hazard ratio (95% CI)⁺	p-value^§
Overall
All-cause mortality	27 (8)	34 (10)	0.77 (0.47–1.28)	0.315
IPF-related mortality^ƒ	18 (5)	28 (8)	0.62 (0.35–1.13)	0.117
On treatment^##
All-cause mortality	19 (6)	29 (8)	0.65 (0.36–1.16)	0.141
IPF-related mortality^ƒ	12 (3)	25 (7)	0.48 (0.24–0.95)	0.030

Data are presented as n (%), unless otherwise stated. ^#: n=345; ^¶: n=347; ⁺: based on the Cox proportional hazard model; ^§: log-rank test (pirfenidone versus placebo); ^ƒ: assessed by the investigator, who remained blinded to treatment assignment; ^##: defined as the time from randomisation until 28 days after the last dose of study drug. Reproduced from [38] with permission from the publisher.